Log in

Immunovant Stock Forecast, Price & News

-0.71 (-1.44 %)
(As of 11/24/2020 12:00 AM ET)
Today's Range
Now: $48.67
50-Day Range
MA: $44.97
52-Week Range
Now: $48.67
Volume189,228 shs
Average Volume352,605 shs
Market Capitalization$4.76 billion
P/E RatioN/A
Dividend YieldN/A
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.57 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:IMVT



Sales & Book Value

Annual SalesN/A



Market Cap$4.76 billion
Next Earnings Date2/12/2021 (Estimated)
OptionableNot Optionable
-0.71 (-1.44 %)
(As of 11/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IMVT News and Ratings via Email

Sign-up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Immunovant (NASDAQ:IMVT) Frequently Asked Questions

How has Immunovant's stock price been impacted by COVID-19?

Immunovant's stock was trading at $14.14 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IMVT stock has increased by 244.2% and is now trading at $48.67.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Immunovant?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last year. There are currently 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Immunovant

What stocks does MarketBeat like better than Immunovant?

Wall Street analysts have given Immunovant a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Immunovant wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Immunovant's next earnings date?

Immunovant is scheduled to release its next quarterly earnings announcement on Friday, February 12th 2021.
View our earnings forecast for Immunovant

How were Immunovant's earnings last quarter?

Immunovant, Inc. (NASDAQ:IMVT) released its quarterly earnings data on Thursday, November, 12th. The company reported ($0.25) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.31) by $0.06.
View Immunovant's earnings history

What price target have analysts set for IMVT?

16 Wall Street analysts have issued 1-year price targets for Immunovant's stock. Their forecasts range from $27.00 to $64.00. On average, they anticipate Immunovant's stock price to reach $47.75 in the next year. This suggests that the stock has a possible downside of 1.9%.
View analysts' price targets for Immunovant

Who are some of Immunovant's key competitors?

What other stocks do shareholders of Immunovant own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include salesforce.com (CRM), NVIDIA (NVDA), Advanced Micro Devices (AMD), The Walt Disney (DIS), Fulcrum Therapeutics (FULC), Myovant Sciences (MYOV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.com (JD) and Johnson & Johnson (JNJ).

Who are Immunovant's key executives?

Immunovant's management team includes the following people:
  • Dr. Peter Salzmann M.B.A., M.D., CEO & Director (Age 53, Pay $1.09M)
  • Ms. Pamela Yanchik Connealy M.B.A., Chief Financial Officer (Age 58, Pay $544.84k)
  • Dr. Julia G. Butchko Ph.D., Chief Devel. & Technology Officer (Age 49)
  • Dr. Michael J. Elliott MBBS, Ph.D., Chief Scientific Officer (Age 61)
  • Dr. Alan Jacobs M.D., VP & Head of Neurology Devel.
  • Dr. Ann M. Daus, VP & Head of Global Quality

What is Immunovant's stock symbol?

Immunovant trades on the NASDAQ under the ticker symbol "IMVT."

Who are Immunovant's major shareholders?

Immunovant's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.02%), Polar Capital LLP (1.79%), Polar Capital LLP (1.79%), Point72 Asset Management L.P. (1.72%), Perceptive Advisors LLC (1.59%) and State Street Corp (1.31%). Company insiders that own Immunovant stock include Julia G Butchko and Sciences Ltd Roivant.
View institutional ownership trends for Immunovant

Which institutional investors are selling Immunovant stock?

IMVT stock was sold by a variety of institutional investors in the last quarter, including Camber Capital Management LP, Polar Capital LLP, Polar Capital LLP, Jane Street Group LLC, Quantitative Systematic Strategies LLC, SG Americas Securities LLC, Morgan Stanley, and Signaturefd LLC.
View insider buying and selling activity for Immunovant

Which institutional investors are buying Immunovant stock?

IMVT stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., BlackRock Inc., State Street Corp, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Perceptive Advisors LLC, Vivo Capital LLC, and Peregrine Capital Management LLC. Company insiders that have bought Immunovant stock in the last two years include Julia G Butchko, and Sciences Ltd Roivant.
View insider buying and selling activity for Immunovant

How do I buy shares of Immunovant?

Shares of IMVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Immunovant's stock price today?

One share of IMVT stock can currently be purchased for approximately $48.67.

How big of a company is Immunovant?

Immunovant has a market capitalization of $4.76 billion. Immunovant employs 42 workers across the globe.

What is Immunovant's official website?

The official website for Immunovant is www.immunovant.com.

How can I contact Immunovant?

Immunovant's mailing address is 320 WEST 37TH STREET, NEW YORK NY, 10018. The company can be reached via phone at 917-580-3099.

This page was last updated on 11/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.